Thalidomide Helps Refractory UC Patients Achieve and Maintain Remission

Thalidomide Helps Refractory UC Patients Achieve and Maintain Remission
Results from an 8-week clinical trial coupled with an 8-week trial extension show evidence that children with refractory ulcerative colitis (UC) can achieve and maintain remission when treated with the small molecule drug thalidomide. The trial, a pilot effort from multiple medical centers in Italy, evaluated 26 children treated with either thalidomide or placebo. The researchers found that thalidomide-treated children maintained clinical remission for an average of 135 weeks, whereas placebo-treated children maintained clinical remission for only 8 weeks. "Twenty-six children with refractory UC were randomized to thalidomide or placebo," stated lead author Marzia Lazzerini, DTMH, MSc, PhD, in the study, "Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *